Retatrutide triple hormone receptor agonist for obesity
study006
10.1056/NEJMoa2301972
New England Journal of Medicine
phase 2 clinical trial
Retatrutide investigated as GLP-1/GIP/glucagon receptor agonist for obesity treatment.
Marked reductions in body weight were reported in phase 2 trials.
retatrutide
fat-loss|metabolism
advanced-metabolic-stack
retatrutide-vs-tirzepatide
published